ClinicalTrials.gg
TerminatedNCT04288011Updated Sep 30, 2026

Validation of the BeCare Multiple Sclerosis Assessment App

An observational study in Multiple Sclerosis, sponsored by BeCare Link LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by BeCare Link LLC · Observational

How we know

Why this study was terminated
Study was ended because of COVID19. Patients did not want to come to hospital for continued participation
Updated Sep 30, 2026Now TerminatedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
231st of 302
30 · median 100
Started
2021
with 80 others
Observational
302 of 1,192
51 open now
Registered
790th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 231st largest by enrollment of the 302 observational ones that give a count, is one of 81 that started in 2021, is one of 302 observational ones, and was the 790th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study involves data collection from use of the BeCare Link LLC mobile device app by subjects with Multiple Sclerosis.

Read the detailed description

Subjects will be enrolled in the study over a period of 12 months beginning at the time of IRB approval or until a complete data set is collected on 50 subjects. This will be a longitudinal study following individual patients for six months and data collection for all patients will continue for a total of 18 months. Patients will be enrolled during their first visit. Additionally, at the first visit for each patient, an EDSS score will be measured, app training performed, and the first app-obtained measurements entered. The patients will be contacted by the research assistant to complete the app tasks on a weekly basis. Clinical EDSS scores will be measured in the clinic at 3 month and 6 month follow-up appointments Research personnel at the Clinical Site will screen for eligible subjects and obtain informed consent. The data collected from the application will continue to be sent to the sponsor.

The purpose of the BeCare App is to replicate the clinically-derived EDSS score. Because the app can be used independently by the patients at more frequent intervals, use of the app may lead to earlier detection of a decline in function than would be possible by clinic evaluations; the app would measure function utilizing data that closely parallels the clinically obtained EDSS score. In the clinic it may take up to two years before someone is noted to have progressive features. The implication of using the BeCare MS App is earlier intervention with switching to more effective Disease Modifying Treatment. Further, as the BeCare App has a cognitive assessment component not routinely performed during follow-up clinical visits, the need for earlier intervention may result in more effective therapy and, therefore, slowed disease progression.

The EDSS is scored by first assessing Human Functional systems (FS) scores. These systems include Sensory, Bowel\& Bladder, Cerebral, Ambulation and Visual. Function System Scores correspond to the amount of observed disability in that system. Low scores 0 represent no disability in that system, to a maximum score representing high disability.

Clinicians then assess EDSS scores from these Functional System scores (FS) according to their experience with patients. The EDSS is scored according to the following:

0 Normal neurological exam, no disability in any FS 1.0 No disability, minimal signs in one FS 1.5 No disability, minimal signs in more than one FS 2.0 Minimal disability in one FS 2.5 Mild disability in one FS or minimal disability in two FS 3.0 Moderate disability in one FS, or mild disability in three or four FS. No impairment to walking 3.5 Moderate disability in one FS and more than minimal disability in several others. No impairment to walking 4.0 Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5 Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0 Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5 Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m 6.0 Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5 Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting 7.0 Unable to walk beyond approximately 5m even with aid. Essentially restricted to wheelchair; though wheels self in standard wheelchair and transfers alone. Up and about in wheelchair some 12 hours a day 7.5 Unable to take more than a few steps. Restricted to wheelchair and may need aid in transferring. Can wheel self but cannot carry on in standard wheelchair for a full day and may require a motorised wheelchair 8.0 Essentially restricted to bed or chair or pushed in wheelchair. May be out of bed itself much of the day. Retains many self-care functions. Generally has effective use of arms 8.5 Essentially restricted to bed much of day. Has some effective use of arms retains some self-care functions 9.0 Confined to bed. Can still communicate and eat 9.5 Confined to bed and totally dependent. Unable to communicate effectively or eat/swallow 10.0 Death due to MS

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • MS
  • mobile app
  • machine learning
  • EDSS
  • BeCare
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with mild to moderate Multiple Sclerosis that can use a mobile app and are ambulatory.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A history of Multiple Sclerosis, which will be verified through medical records and will be classified as clinically definite based on revised McDonald criteria
  2. Between the ages 18-75
  3. Mild to moderate disability in one or more of the modalities assessed by the BeCare App.
  4. Ability to provide .

Exclusion criteria

Exclusion Criteria:

  1. Subjects at risk of falling
  2. Subjects with poor vision that cannot read the screen of a mobile phone
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Clinical EDSS

    The Kurtzke EDSS, is a clinical rating scale for multiple sclerosis having scores between 0 to 10 that are assigned by a trained clinician. Smaller impairments are assessed at lower scores and disability is assessed at higher scores. It is important to note, however, that despite being denoted on an ordinal scale, each level on the scale is not indicative of an equal change in disability.

  • MLA EDSS

    The Kurtzke EDSS, is a clinical rating scale or multiple sclerosis having scores between 0 to 10 that are assigned by a technique based upon several different Machine Learning Algorithms that are combined to produce a single score

06

What researchers measure

Primary outcomes

  1. Clinical EDSS score vs MLA EDSS score comparison

    To assess the efficacy of using a mobile application to perform routine assessments of neurological and physical functioning in subjects with MS by comparing clinically assigned EDSS scores with EDSS scores assigned by a single or multiple artificial intelligence techniques at various timed intervals

    Time frame: day 1 (initial visit)

  2. Clinical EDSS score vs MLA EDSS score comparison

    To assess the efficacy of using a mobile application to perform routine assessments of neurological and physical functioning in subjects with MS by comparing clinically assigned EDSS scores with EDSS scores assigned by a single or multiple artificial intelligence techniques at various timed intervals

    Time frame: 90 days after day 1

  3. Clinical EDSS score vs MLA EDSS score comparison

    To assess the efficacy of using a mobile application to perform routine assessments of neurological and physical functioning in subjects with MS by comparing clinically assigned EDSS scores with EDSS scores assigned by a single or multiple artificial intelligence techniques at various timed intervals

    Time frame: 180 days after day 1

Secondary outcomes

  1. Disease Progression Measured by Change in EDSS score

    To improve the understanding of disease progression over a shorter time interval captured by weekly BeCare application's monitoring.

    Time frame: weekly for 26 weeks

  2. Development of a novel application to measure change in MS

    To assist in the development of a novel application that is easy to use and is capable of evaluating MS patients' neurological and physical functioning outside the clinical setting, that allows both patients and clinicians to view their disease progression over time. The data this application will collect could prove to be a valuable source of information and may improve how well MS symptoms and functioning can be evaluated by healthcare providers.

    Time frame: 18 months

07

Study locations

1 site
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
08

References and documents

Publications

  • Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366. PubMed 21387374 ↗
  • Sebastiao E, Sandroff BM, Learmonth YC, Motl RW. Validity of the Timed Up and Go Test as a Measure of Functional Mobility in Persons With Multiple Sclerosis. Arch Phys Med Rehabil. 2016 Jul;97(7):1072-7. doi: 10.1016/j.apmr.2015.12.031. Epub 2016 Mar 2. PubMed 26944709 ↗
  • Berrigan LI, Fisk JD, Walker LA, Wojtowicz M, Rees LM, Freedman MS, Marrie RA. Reliability of regression-based normative data for the oral symbol digit modalities test: an evaluation of demographic influences, construct validity, and impairment classification rates in multiple sclerosis samples. Clin Neuropsychol. 2014;28(2):281-99. doi: 10.1080/13854046.2013.871337. Epub 2014 Jan 20. PubMed 24438521 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Dec 2022, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2020
First posted
Feb 27, 2020
StartActual
Feb 26, 2021
Primary completionActual
Dec 20, 2022
CompletionActual
Feb 20, 2023
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated Study was ended because of COVID19. Patients did not want to come to hospital for continued participation
changed Sep 30, 2026
Eligibility
Revised
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Status unknown→Terminated
    Why stopped Study was ended because of COVID19. Patients did not want to come to hospital for continued participation
    Eligibility Revised
    + 3 other changes: index terms, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04288011
Lead sponsor
BeCare Link LLC
Collaborators
Yale University
Responsible party
Sponsor
First posted
Feb 27, 2020
Start date
Feb 26, 2021
Primary completion
Dec 20, 2022
Completion
Feb 20, 2023
Last update
Sep 30, 2026

Study contacts

Sharon Stoll, DO,MS
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion